MedTrace Logo

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-07-10

No results posted yet for this study

Summary

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

Conditions

  • Recurrent Head and Neck Carcinoma
  • Head and Neck Cancer Metastatic
  • Head or Neck Cancer

Interventions

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

DRUG

Cisplatin

RADIATION

Stereotactic Body Radiotherapy (SBRT)

Sponsors & Collaborators

Principal Investigators

  • Jonathan Schoenfeld, MD, MPH · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2021-01-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474368 on ClinicalTrials.gov